Parenchymal liver metastasis in advanced ovarian cancer: Can bowel involvement influence the frequency and the related mortality rate?

Sopracordevole, Francesco; Chiofalo, Benito; Forte, Sara; Ciancio, Fabio; Fiore, Maria; Giorda, Giorgio

doi:10.1016/j.ejogrb.2022.11.008

Cited by 3 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ovarian cancer liver metastasis poses a substantial clinical challenge, contributing signifcantly to the high mortality rates associated with the disease [17]. Trough a comprehensive examination of serous ovarian cancer liver metastasis (OCLM) patients, this study revealed crucial insights into the involvement of alpha kinase 2 (ALPK2) in both in vivo and in vitro settings.…”

Section: Discussionmentioning

confidence: 99%

The Influence of Alpha Kinase 2 Expression on Prognosis in Serous Ovarian Cancer Liver Metastasis

Sun,

Zhang,

et al. 2024

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

Background. Globally, ovarian cancer is a leading contributor to cancer-related fatalities among women, with a notable concern being the occurrence of liver metastasis as a prevalent clinical complication. This study aims to investigate the potential impact of alpha kinase 2 (ALPK2) on ovarian cancer liver metastasis (OCLM), assessing its implications for patient prognosis and tumor advancement. Our research seeks to examine the prognostic significance of ALPK2 in individuals with OCLM and unravel the consequences of ALPK2 knockdown on the proliferation and invasion of ovarian cancer cells. Methods. A retrospective analysis of 49 OCLM cases from our medical center was conducted to evaluate the prognostic significance of ALPK2 through survival analyses. Experimental investigations involved the use of shRNA to knock down ALPK2 in ovarian cancer cell lines, with subsequent scrutiny of cellular changes. Results. Survival analyses revealed that ALPK2 functions as an independent adverse prognostic factor in OCLM (HR = 3.74, 95% CI: 1.34–10.42, and P=0.012). Knockdown experiments indicated a reduction in cell proliferation and invasion capacities, potentially associated with the epithelial-mesenchymal transition process. Conclusions. ALPK2 emerges as a crucial oncogene promoting tumors in OCLM. Its knockdown exhibits significant therapeutic potential by hindering cancer progression. Further investigations could solidify the role and therapeutic possibilities of ALPK2 in the treatment of ovarian cancer, particularly in cases involving liver metastasis.

show abstract

Section: Discussionmentioning

confidence: 99%

The Influence of Alpha Kinase 2 Expression on Prognosis in Serous Ovarian Cancer Liver Metastasis

Sun,

Zhang,

et al. 2024

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

show abstract

“…In that case, the distal sigmoid is frequently involved. The depth of the colorectal wall invasion is an important prognostic factor 5. Despite serosal implantation through the distal sigmoid is quite common, metastasis of ovarian cancer intraluminal is rare and atypical.…”

Section: Introductionmentioning

confidence: 99%

“…There is growing evidence that patients without visible disease have better survival than those with macroscopic residual disease 7. To achieve these complete resections, additional bowel resection is needed in 10%–70% of all advanced ovarian carcinomas 5…”

Section: Introductionmentioning

confidence: 99%

Endoscopic full-thickness resection of a solitary ovarian carcinoma colorectal metastasis

Schreuder,

Stoop,

Piek

et al. 2024

BMJ Case Rep

View full text Add to dashboard Cite

A woman in her 70s with a medical history of recurrent ovarian carcinoma was referred to the gastroenterologist because of rectal blood loss. Colonoscopy revealed a spontaneously bleeding lesion, which was not a typical colorectal carcinoma by optical diagnosis. Biopsies confirmed the diagnosis of recurrence of the former ovarian carcinoma. The patient was not eligible for surgical resection due to former abdominal surgery and she declined chemotherapy due to severe side effects earlier. After a multidisciplinary team consultation, she was treated with endoscopic full-thickness resection (eFTR). This is a minimally invasive resection technique for removal of challenging colorectal lesions. The patient has recovered well and 2 years after the metastasis resection with eFTR there still have been no signs of recurrent malignancy.

show abstract

“…Despite the fact that over 50% of patients can attain remission through standard treatment procedures [5], resistance to platinum-based chemotherapeutic agents and molecular targeted therapeutic drugs remain a common occurrence. However, there are restrictions on the variety and effectiveness of suitable targeted medications, and ovarian cancer has a tendency to relapse and spread following the initial treatment recovery [6]. Treating end stage or recurring ovarian cancer has become increasingly challenging due to the absence of efficient medications.…”

Section: Introductionmentioning

confidence: 99%

Exploring the molecular mechanisms and potential therapeutic strategies of ferroptosis in ovarian cancer

MA,

SHAO,

ZHU

2024

BIOCELL

View full text Add to dashboard Cite

The morbidity rate of ovarian cancer, a malignant tumour in gynaecological tumours, is rising, and it is considered to be the most lethal cancer. The majority of patients are typically diagnosed during the advanced stages of the illness due to the elusive characteristics of ovarian cancer and an absence of highly sensitive and specific diagnostic indicators. Surgical excision of the lesions, along with chemotherapy, is the conventional treatment for ovarian cancer; however, resistance to platinum-based chemotherapeutic drugs and molecular targeted therapies frequently arises. Improving the survival rate and prognosis of patients with end-stage or recurring ovarian cancer requires the identification of new therapeutic targets due to the absence of efficient medications, and this has emerged as a highly demanding issue. Studies have demonstrated that ferroptosis effectively hinders the proliferation of ovarian cancer and induces the demise of malignant cells. Ferroptosis is composed of the cystine/glutamate antiporter system (the system Xc-) and glutathione peroxidase 4 (GPX4). Solute carrier family 7 member 11 (SLC7A11) and solute carrier family 3 member 2 (SLC3A2) play crucial roles in the regulation of ferroptosis by facilitating the uptake of cystine into cells and the efflux of glutamate out of cells, respectively. In cells, GPX4 is the exclusive enzyme employed for reducing liposomal peroxide through glutathione peroxidase activity. The occurrence of ferroptosis in ovarian cancer is strongly associated with three main pathways, namely, the GPX4-glutathione (GSH) protective pathway, the ferroptosis suppressor protein 1 (FSP1)-coenzyme Q10 (CoQ10) protective pathway, and the guanosine 5'-triphosphate cyclohydrolase I (GCH1) protective pathway. In ovarian cancer cells, the postsynaptic density-95, discs-large, zona occludens 1 (PDZ)-binding motif-angiopoietin-like 4-nicotinamide adenine dinucleotide phosphate oxidases 2 (TAZ-ANGPTL4-NOX2) pathway can be regulated by Yes-associated protein (YAP)/TAZ, a downstream component of the Hippo pathway, leading to the modulation of ferroptosis. By targeting microRNA-587, lncRNA ADAMTS9 antisense RNA 1 (ADAMTS9-AS1) can modulate the expression of SLC7A11 and reduce the occurrence of ferroptosis. Although ferroptosis holds promise in overcoming the resistance mechanism, there remain obstacles in utilizing it as a cancer treatment, including the potential harm of drugs to healthy cells. Hence, additional investigations are required to formulate safer and more efficient chemotherapy protocols for the treatment of ovarian cancer and other malignancies.

show abstract

Parenchymal liver metastasis in advanced ovarian cancer: Can bowel involvement influence the frequency and the related mortality rate?

Cited by 3 publications

References 30 publications

The Influence of Alpha Kinase 2 Expression on Prognosis in Serous Ovarian Cancer Liver Metastasis

The Influence of Alpha Kinase 2 Expression on Prognosis in Serous Ovarian Cancer Liver Metastasis

Endoscopic full-thickness resection of a solitary ovarian carcinoma colorectal metastasis

Exploring the molecular mechanisms and potential therapeutic strategies of ferroptosis in ovarian cancer

Contact Info

Product

Resources

About